157 related articles for article (PubMed ID: 38339323)
1. Inhibition of Enhancer of Zeste Homolog 2 Induces Blast Differentiation, Impairs Engraftment and Prolongs Survival in Murine Models of Acute Myeloid Leukemia.
Fobare S; Elgamal OA; Wunderlich M; Stahl E; Mehmood A; Furby C; Lerma JR; Sesterhenn TM; Pan J; Rai J; Johnstone ME; Abdul-Aziz A; Johnson ML; Rai SN; Byrd JC; Hertlein E
Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339323
[TBL] [Abstract][Full Text] [Related]
2. Nanoformulation of EPZ011989 Attenuates EZH2-c-Myb Epigenetic Interaction by Proteasomal Degradation in Acute Myeloid Leukemia.
Kaundal B; Srivastava AK; Dev A; Mohanbhai SJ; Karmakar S; Roy Choudhury S
Mol Pharm; 2020 Feb; 17(2):604-621. PubMed ID: 31904978
[TBL] [Abstract][Full Text] [Related]
3. EZH2/EHMT2 Histone Methyltransferases Inhibit the Transcription of DLX5 and Promote the Transformation of Myelodysplastic Syndrome to Acute Myeloid Leukemia.
Zheng Z; Li L; Li G; Zhang Y; Dong C; Ren F; Chen W; Ma Y
Front Cell Dev Biol; 2021; 9():619795. PubMed ID: 34409024
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo/Gli-1 pathway in acute myeloid leukemia.
Jiang X; Jiang L; Cheng J; Chen F; Ni J; Yin C; Wang Q; Wang Z; Fang D; Yi Z; Yu G; Zhong Q; Carter BZ; Meng F
J Transl Med; 2021 Mar; 19(1):117. PubMed ID: 33743723
[TBL] [Abstract][Full Text] [Related]
5. A non-viral nano-delivery system targeting epigenetic methyltransferase EZH2 for precise acute myeloid leukemia therapy.
Kaundal B; Kushwaha AC; Srivastava AK; Karmakar S; Choudhury SR
J Mater Chem B; 2020 Sep; 8(37):8658-8670. PubMed ID: 32844866
[TBL] [Abstract][Full Text] [Related]
6. Quantitative proteomic analysis of EZH2 inhibition in acute myeloid leukemia reveals the targets and pathways that precede the induction of cell death.
Sandow JJ; Infusini G; Holik AZ; Brumatti G; Averink TV; Ekert PG; Webb AI
Proteomics Clin Appl; 2017 Sep; 11(9-10):. PubMed ID: 28447382
[TBL] [Abstract][Full Text] [Related]
7. Targeting EZH2 Promotes Chemosensitivity of BCL-2 Inhibitor through Suppressing PI3K and c-KIT Signaling in Acute Myeloid Leukemia.
Yang C; Gu Y; Ge Z; Song C
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232694
[TBL] [Abstract][Full Text] [Related]
8. Targeting EZH2-mediated methylation of histone 3 inhibits proliferation of pediatric acute monocytic leukemia cells
Al-Ghabkari A; Narendran A
Cancer Biol Ther; 2021 Apr; 22(4):333-344. PubMed ID: 33978549
[TBL] [Abstract][Full Text] [Related]
9. E2F4 functions as a tumour suppressor in acute myeloid leukaemia via inhibition of the MAPK signalling pathway by binding to EZH2.
Feng Y; Li L; Du Y; Peng X; Chen F
J Cell Mol Med; 2020 Feb; 24(3):2157-2168. PubMed ID: 31943751
[TBL] [Abstract][Full Text] [Related]
10. Long noncoding RNA HOTAIR promotes the self-renewal of leukemia stem cells through epigenetic silencing of p15.
Gao S; Zhou B; Li H; Huang X; Wu Y; Xing C; Yu X; Ji Y
Exp Hematol; 2018 Nov; 67():32-40.e3. PubMed ID: 30172749
[TBL] [Abstract][Full Text] [Related]
11. ELK1-Induced upregulation of long non-coding TNK2-AS1 promotes the progression of acute myeloid leukemia by EZH2-mediated epigenetic silencing of CELF2.
Guo D; Zhang A; Suo M; Wang P; Liang Y
Cell Cycle; 2023 Jan; 22(1):117-130. PubMed ID: 35941836
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic vulnerabilities of leukemia harboring inactivating EZH2 mutations.
Alqazzaz MA; Luciani GM; Vu V; Machado RAC; Szewczyk MM; Adamson EC; Cheon S; Li F; Arrowsmith CH; Minden MD; Barsyte-Lovejoy D
Exp Hematol; 2024 Feb; 130():104135. PubMed ID: 38072134
[TBL] [Abstract][Full Text] [Related]
13. Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.
Göllner S; Oellerich T; Agrawal-Singh S; Schenk T; Klein HU; Rohde C; Pabst C; Sauer T; Lerdrup M; Tavor S; Stölzel F; Herold S; Ehninger G; Köhler G; Pan KT; Urlaub H; Serve H; Dugas M; Spiekermann K; Vick B; Jeremias I; Berdel WE; Hansen K; Zelent A; Wickenhauser C; Müller LP; Thiede C; Müller-Tidow C
Nat Med; 2017 Jan; 23(1):69-78. PubMed ID: 27941792
[TBL] [Abstract][Full Text] [Related]
14. MEK/ERK and PI3K/AKT pathway inhibitors affect the transformation of myelodysplastic syndrome into acute myeloid leukemia via H3K27me3 methylases and de‑methylases.
Zheng Z; Chen X; Zhang Y; Ren F; Ma Y
Int J Oncol; 2023 Dec; 63(6):. PubMed ID: 37921060
[TBL] [Abstract][Full Text] [Related]
15. Multiparametric analysis of apoptotic and multi-drug resistance phenotypes according to the blast cell maturation stage in elderly patients with acute myeloid leukemia.
Suárez L; Vidriales B; García-Laraña J; López A; Martínez R; Martín-Reina V; Tormo M; González-San Miguel JD; Lavilla E; García-Boyero R; Orfao A; San Miguel JF;
Haematologica; 2001 Dec; 86(12):1287-95. PubMed ID: 11726321
[TBL] [Abstract][Full Text] [Related]
16. Dual inhibition of EZH2 and G9A/GLP histone methyltransferases by HKMTI-1-005 promotes differentiation of acute myeloid leukemia cells.
Sbirkov Y; Schenk T; Kwok C; Stengel S; Brown R; Brown G; Chesler L; Zelent A; Fuchter MJ; Petrie K
Front Cell Dev Biol; 2023; 11():1076458. PubMed ID: 37035245
[TBL] [Abstract][Full Text] [Related]
17. Histone methyltransferase EZH2 epigenetically affects CCNA1 expression in acute myeloid leukemia.
Yang X; Wan M; Yu F; Wu X
Cell Signal; 2021 Nov; 87():110144. PubMed ID: 34509612
[TBL] [Abstract][Full Text] [Related]
18. HO-1 promotes resistance to an EZH2 inhibitor through the pRB-E2F pathway: correlation with the progression of myelodysplastic syndrome into acute myeloid leukemia.
He Z; Zhang S; Ma D; Fang Q; Yang L; Shen S; Chen Y; Ren L; Wang J
J Transl Med; 2019 Nov; 17(1):366. PubMed ID: 31711520
[TBL] [Abstract][Full Text] [Related]
19. Long noncoding RNA HOXA-AS2 functions as an oncogene by binding to EZH2 and suppressing LATS2 in acute myeloid leukemia (AML).
Feng Y; Hu S; Li L; Peng X; Chen F
Cell Death Dis; 2020 Dec; 11(12):1025. PubMed ID: 33268767
[TBL] [Abstract][Full Text] [Related]
20. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.
Fiskus W; Wang Y; Sreekumar A; Buckley KM; Shi H; Jillella A; Ustun C; Rao R; Fernandez P; Chen J; Balusu R; Koul S; Atadja P; Marquez VE; Bhalla KN
Blood; 2009 Sep; 114(13):2733-43. PubMed ID: 19638619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
